Reading OSTX? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track OSTX free→Reading OSTX? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track OSTX free→QuarterlyIQ Insights · OSTX
Material updates from SEC filings (8-K, 10-Q, 10-K) ranked by impact, with no firehose noise.
Entry into a Material Definitive Agreement. Securities Purchase Agreement On March 31, 2026, OS Therapies Incorporated (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with the purchasers identified on the signature pages thereto (the “Purchasers”), pursuant to which the Company offered for sale to the Purchasers in a registered direct offering (the “Offering”) an aggregate of 2,505,073 shares of its common stock and, in lieu thereof, pre-funded warrants…
Other Events. On March 31, 2026, OS Therapies Incorporated (the “Company”) filed with the U.S. Securities and Exchange Commission (the “SEC”) a prospectus supplement (the “Prospectus Supplement”), which forms a part of the Company’s registration statement on Form S-3 (File No. 333-289443), which was previously filed with the SEC on August 8, 2025 and declared effective on August 12, 2025. The Prospectus Supplement covers the resale from time to time of up to 10,529,417 shares of the Company’s…
Entry into a Material Definitive Agreement. Private Placement On March 4, 2026, OS Therapies Incorporated (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with certain accredited investors (collectively, the “Purchasers”), pursuant to which the Company agreed to issue and sell to the Purchasers, in a private placement (the “Private Placement”), (i) 10.0% original issue discount unsecured convertible promissory notes (the “Notes”) and (ii) warrants to pur…
Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. The information set forth under
The Notes, Warrants and Underlying Shares are being offered and sold by the Company in reliance upon an exemption from the registration requirements of the Securities Act of 1933, as amended (the “Securities Act”), afforded by Section 4(a)(2) thereof and/or Regulation D promulgated thereunder. The Purchasers represented that they are “accredited investors” as defined in Rule 501(a) under the Securities Act.
The New Warrants and New Warrant Shares are being offered and sold by the Company in reliance upon an exemption from the registration requirements of the Securities Act afforded by Section 4(a)(2) of the Securities Act and Rule 506(b) of Regulation D promulgated thereunder.
Entry into a Material Definitive Agreement. Warrant Exercise Inducement On January 10, 2026, OS Therapies Incorporated (the “Company”) entered into inducement offer letter agreements (the “Inducement Letters”) with less than 10 accredited investors (the “Holders”) that hold certain existing warrants of the Company to purchase up to an aggregate of 5,382,148 shares of the Company’s common stock, originally issued to the Holders in connection with the Company’s previous warrant exercise inducem…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On October 21, 2025, the stockholders of OS Therapies Incorporated (the “Company”) approved and adopted an amendment (the “Plan Amendment”) to the Company’s 2023 Incentive Compensation Plan, as amended (the “Plan”), at its 2025 annual meeting of stockholders (the “Annual Meeting”). A summary of the material terms of the Plan, as amended by the Plan…
Other Events. On September 30, 2025, OS Therapies Incorporated (the “Company”) filed with the U.S. Securities and Exchange Commission (the “SEC”) a prospectus supplement (the “Prospectus Supplement”), which forms a part of the Company’s registration statement on Form S-3 (File No. 333-289443), which was previously filed with the SEC on August 8, 2025 and declared effective on August 12, 2025. The Prospectus Supplement covers the resale from time to time of up to 4,373,043 shares of the Compan…
Entry into a Material Definitive Agreement. Warrant Exercise Inducement On September 2, 2025, OS Therapies Incorporated (the “Company”) closed on a second warrant exercise inducement and exchange offer (the “Offering”). The Offering was made to remaining holders (the “Remaining Holders”) of the existing warrants of the Company to purchase shares of the Company’s common stock, having a current exercise price of $1.12 per share, originally issued to the Remaining Holders on December 31, 2024 an…
The New Warrants and New Warrant Shares were offered and sold by the Company in reliance upon an exemption from the registration requirements of the Securities Act afforded by Section 4(a)(2) of the Securities Act and Rule 506(b) of Regulation D promulgated thereunder.
Termination of a Material Definitive Agreement. On August 25, 2025, OS Therapies Incorporated (the “Company”) delivered to Square Gate Capital Master Fund, LLC — Series 3 (“Square Gate”) a notice to terminate the Equity Purchase Agreement, dated as of October 31, 2024 (the “ELOC Purchase Agreement”), pursuant to Section 10.6 thereof. The termination became effective on August 26, 2025. As previously disclosed, the ELOC Purchase Agreement provided the Company with the right to sell to Square G…
Results of Operations and Financial Condition. On August 19, 2025, OS Therapies Incorporated, a clinical-stage cancer immunotherapy and ADC biotechnology company, issued a press release announcing its financial results for the quarter ended June 30, 2025 and providing a business update. A copy of the press release is furnished with this report as Exhibit 99.1. Such information, including Exhibit 99.1 attached hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exc…
The New Warrants and New Warrant Shares were offered and sold by the Company in reliance upon an exemption from the registration requirements of the Securities Act afforded by Section 4(a)(2) of the Securities Act and Rule 506(b) of Regulation D promulgated thereunder.
Entry into a Material Definitive Agreement. Warrant Exercise Inducement On July 11, 2025, OS Therapies Incorporated (the “Company”) completed a final closing of the warrant exercise inducement and exchange offer (the “Offering”) previously reported by the Company in its Current Reports on Form 8-K filed with the Securities and Exchange Commission (the “SEC”) on June 24, 2025 and June 27, 2025, which are incorporated herein by reference. The Offering was made to holders (the “Holders”) of cert…
The New Warrants and New Warrant Shares are being offered and sold by the Company in reliance upon an exemption from the registration requirements of the Securities Act afforded by Section 4(a)(2) of the Securities Act and Rule 506(b) of Regulation D promulgated thereunder. 3 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. OS THERAPIES INCORPORATED…
Entry into a Material Definitive Agreement. Warrant Exercise Inducement On June 26, 2025, OS Therapies Incorporated (the “Company”) completed a second closing of the warrant exercise inducement and exchange offer (the “Offering”) previously reported by the Company in its Current Report on Form 8-K filed with the Securities and Exchange Commission (the “SEC”) on June 24, 2025, which is incorporated herein by reference. As previously reported, in connection with the Offering, on June 23, 2025,…
Entry into a Material Definitive Agreement. Warrant Exercise Inducement On June 23, 2025, OS Therapies Incorporated (the “Company”) entered into inducement offer letter agreements (the “Inducement Letters”) with holders (the “Holders”) of certain existing warrants of the Company to purchase up to an aggregate of 1,574,288 shares of the Company’s common stock, having a current exercise price of $1.12 per share, originally issued to the Holders on December 31, 2024 and/or January 14, 2025 (the…
The New Warrants and New Warrant Shares are being offered and sold by the Company in reliance upon an exemption from the registration requirements of the Securities Act afforded by Section 4(a)(2) of the Securities Act and Rule 506(b) of Regulation D promulgated thereunder.
Results of Operations and Financial Condition. On May 16, 2025, OS Therapies Incorporated, a clinical-stage cancer immunotherapy and ADC biotechnology company, issued a press release announcing its financial results for the quarter ended March 31, 2025. A copy of the press release is furnished with this report as Exhibit 99.1. Such information, including Exhibit 99.1 attached hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor…
Results of Operations and Financial Condition. On March 31, 2025, OS Therapies Incorporated, a clinical-stage cancer immunotherapy and ADC biotechnology company, issued a press release announcing its financial results for the quarter and year ended December 31, 2024. A copy of the press release is furnished with this report as Exhibit 99.1. Such information, including Exhibit 99.1 attached hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, a…
Other Events. On January 29, 2025, the Company issued a press release announcing the acquisition of the Assets, the appointment of Mr. Galzahr and certain clinical data conclusions of the Company’s lung cancer asset. The full text of the press release, a copy of which is attached hereto as Exhibit 99.1, is incorporated herein by reference. Cautionary Note Regarding Forward-Looking Statements This report, including Exhibit 99.1, contains “forward-looking statements” within the meaning of the f…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On January 28, 2025, Karim Galzahr was elected to the Company’s board of directors. Mr. Galzahr has not been appointed to any committee of the board at this time. Mr. Galzahr was elected to the Company’s board in accordance with the terms of the previously disclosed Securities Purchase Agreement, dated as of December 30, 2024, by and among the Comp…
Entry into a Material Definitive Agreement. On January 28, 2025, OS Therapies Incorporated (“OS Therapies” or the “Company”) entered into an Asset Purchase Agreement (the “Purchase Agreement”) with Ayala Pharmaceuticals, Inc., a Delaware corporation formerly known as Advaxis, Inc. (“Ayala” or the “Seller”), pursuant to which the Company agreed, subject to the terms and conditions set forth therein, to acquire from Ayala all HER2 and Listeria monocytogenes ( Lm ) related intellectual property…
The Consideration Shares, Warrant (including Warrant Shares) and Additional Consideration Shares (if any) are being offered and sold by the Company to Ayala under the Purchase Agreement in reliance upon an exemption from the registration requirements of the Securities Act afforded by Section 4(a)(2) of the Securities Act and Rule 506(b) of Regulation D promulgated thereunder.
General market headlines, full earnings-call transcripts, and macro and sector developments flagged when they directly affect this stock are on the way. Today this tab covers SEC filings.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.